CRISPR Therapeutics is exiting the “valley of death”: Casgevy’s delayed revenue conversion and a wholly-owned in vivo platform create a cash-backed setup for a potential multi-year re-rating—if execution and IP risk cooperate.
Overview
CRISPR Therapeutics is transitioning from clinical-stage innovator to commercial biopharma after achieving a historic milestone: **Casgevy**, the first FDA-approved CRISPR/Cas9 gene-editing therapy, for SCD and TDT (partnered with Vertex). The thesis has evolved from platform speculation to a practical question of **commercial execution, reimbursement, and manufacturing throughput** for a complex autologous therapy with a long vein-to-vein cycle. Although initial launch revenue recognition in 2024–2025 lagged optimistic expectations due to treatment logistics, the trend into 2026 points to acceleration as backlog converts; Vertex guided to **>$100M Casgevy revenue in 2025** with meaningful growth expected in 2026. The company’s second and potentially higher-upside value pillar is its **wholly-owned in vivo editing portfolio**, highlighted by CTX310’s Phase 1 proof-of-concept for durable lipid lowering, expanding CRSP’s TAM into large chronic cardiometabolic markets. Financially, CRSP is differentiated by a **~$1.94B cash fortress** (Sept 30, 2025), reducing dilution risk and enabling aggressive pipeline development. Key overhangs remain: the unresolved CVC vs Broad IP dispute, operational constraints in the Casgevy rollout (manufacturing slots, center readiness, payer friction), and competitive threats in both hemoglobinopathies and cardiometabolic gene editing.